You can buy or sell FOLD and other stocks, options, and ETFs commission-free!
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Cranbury, NJ. The listed name for FOLD is Amicus Therapeutics, Inc. Common Stock.
John Francis Crowley
52 Week High
52 Week Low
Amicus Therapeutics: Q4 Earnings Insights
Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per s
-$0.23 per share
-$0.27 per share